重大事件
外國發行人報告
6-K
2026-07-07
Lakefront Biotherapeutics回購逾10萬股 平均價€26.24 涉資約298萬美元
AI 繁中摘要
Lakefront Biotherapeutics（前稱Galapagos，代號LKFT）提交6-K表格，披露其股份回購計劃的最新進展。該計劃於2026年6月9日公布，公司在6月29日至7月3日期間，透過歐交所（Euronext Amsterdam、CEUX、TQEX、AQEU）共回購104,022股普通股，每股平均價格€26.24（約$28.6），總代價約€273萬（約$298萬）。回購價格範圍介乎€25.60至€26.88。
截至7月3日收市，Lakefront合共持有303,756股庫存股份。是次回購反映管理層對公司價值的信心，並透過資本回報提升股東價值。公司目前專注於免疫及炎症領域的臨床階段管線，核心資產為潛在同類首創的BCMAxCD3 T細胞銜接器gamgertamig，用於自身免疫疾病。憑藉穩健的資產負債表及交易能力，公司持續推進高潛力資產。
投資者應注意，回購行動有助於支撐股價及提高每股盈利，但最終成效仍取決於臨床進展及市場環境。詳細風險請參閱公司向SEC提交的20-F年報及後續文件。
展開英文正文
EX-99.1
2
exh_991.htm
PRESS RELEASE
EdgarFiling
EXHIBIT 99.1
Acquisition of Own Shares
Mechelen, Belgium; 07 July 2026, 22.01 CET; regulated information
Within the framework of the repurchase program announced on June 9, 2026, Lakefront Biotherapeutics NV (Euronext &
NASDAQ: LKFT) ("Lakefront") announces that it has repurchased 104,022 Lakefront shares between 29 June 2026 and 03 July 2026, as follows:
Date
of purchase
Market/MTF
Number
of shares
Average
price paid (€)
Total
(€)
Lowest
price paid (€)
Highest
price paid (€)
29/06/2026
XAMS
14,414
25.75
371,205.18
25.60
26.00
29/06/2026
CEUX
3,399
25.74
87,478.36
25.66
26.00
29/06/2026
TQEX
696
25.71
17,897.29
25.66
26.00
29/06/2026
AQEU
916
25.71
23,551.83
25.66
25.80
30/06/2026
XAMS
19,724
26.37
520,179.08
25.98
26.74
30/06/2026
CEUX
2,068
26.45
54,694.67
26.22
26.72
30/06/2026
TQEX
508
26.53
13,478.15
26.14
26.78
30/06/2026
AQEU
445
26.09
11,610.94
26.08
26.12
01/07/2026
XAMS
20,787
26.30
546,681.47
26.06
26.48
01/07/2026
CEUX
2,613
26.20
68,467.39
26.12
26.44
01/07/2026
TQEX
71
26.40
1,874.32
26.32
26.40
01/07/2026
AQEU
198
26.17
5,181.78
26.16
26.30
02/07/2026
XAMS
13,778
26.14
360,180.34
25.88
26.54
02/07/2026
CEUX
3,021
26.06
78,727.86
25.96
26.12
02/07/2026
TQEX
115
26.23
3,015.94
25.96
26.46
02/07/2026
AQEU
721
26.12
18,835.04
25.96
26.14
03/07/2026
XAMS
15,162
26.62
403,642.76
26.46
26.86
03/07/2026
CEUX
4,786
26.59
127,266.92
26.50
26.86
03/07/2026
TQEX
526
26.75
14,071.18
26.50
26.88
03/07/2026
AQEU
74
26.62
1,970.16
26.52
26.64
Total
104,022
26.24
2,730,010.70
25.60
26.88
As of market close on 03 July 2026, Lakefront holds 303,756 of its own ordinary shares.
About Lakefront BiotherapeuticsLakefront Biotherapeutics (formerly known as Galapagos) is a biotechnology
company dedicated to building a differentiated pipeline of medicines for patients with serious diseases in areas of high unmet need. The
Company has established a clinical‑stage portfolio in immunology and inflammation, anchored by gamgertamig, a potential first‑in‑class
BCMAxCD3 T‑cell engager for autoimmune diseases. Backed by deep deal‑making expertise, operational flexibility, and a strong
capital position, Lakefront identifies, acquires, and advances high‑quality assets with clear potential to deliver meaningful patient
impact and long‑term shareholder value. For more information, visit https://www.lakefrontbio.com or follow us on LinkedIn or X.
For further information, contact Lakefront Biotherapeutics:Investor Relations Sherri Spear+1
412 522 [email protected]
Forward-looking statementsThis press release contains forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995, all of which involve certain risks and uncertainties. These statements are often,
but are not always, made through the use of words or phrases such as “believe,” “anticipate,” “expect,”
“intend,” “plan,” “seek,” “upcoming,” “future,” “estimate,” “may,”
“will,” “could,” “would,” “potential,” “forward,” “goal,” “next,”
“continue,” “should,” “encouraging,” “aim,” “progress,” “remain,”
“explore,” and “further,” as well as similar expressions. These statements include, but are not limited to, statements
regarding Lakefront’s plans to repurchase its ordinary shares. Lakefront cautions the reader that forward-looking statements are
based on our management’s current expectations and beliefs and are not guarantees of future performance. Forward-looking statements
may involve known and unknown risks, uncertainties and other factors which might cause actual events, financial condition and liquidity,
performance, or achievements, or the industry in which we operate, to be materially different from any historic or future results, financial
conditions, performance or achievements expressed or implied by such forward-looking statements. In addition, even if our results, performance,
financial condition and liquidity, and the development of the industry in which Lakefront operates are consistent with such forward-looking
statements, they may not be predictive of results or developments in future periods. Such risks include, but are not limited to, those
risks and uncertainties that can be found in our filings and reports with the Securities and Exchange Commission (“SEC”),
including in our most recent annual report on Form 20-F filed with the SEC and our subsequent filings and reports filed with the SEC.
Given these risks and uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements. In addition,
even if the result of our operations, financial condition and liquidity, or the industry in which we operate, are consistent with such
forward-looking statements, they may not be predictive of results, performance or achievements in future periods. These forward-looking
statements speak only as of the date of publication of this release. We expressly disclaim any obligation to update any such forward-looking
statements in this release to reflect any change in our expectations or any change in events, conditions or circumstances, unless specifically
required by law or regulation.